From ketamine to psychedelics, join our webinar starting tomorrow! Sent on 09 May 2022
Long term delayed effects of psychedelics in preclinical models. Trailblazing results revealed! Sent on 05 April 2022
Accreditation awarded with flying colours Sent on 01 March 2022
Breaking news! Merger announcement between Transpharmation and InterVivo Solutions. Sent on 08 February 2022
Take a look! New posters, nine therapeutic areas available to view now. Sent on 01 December 2021
Nine new compelling studies to be revealed at SfN21! Sent on 03 November 2021
Can changes in EEG improve neuropathic pain treatments? Sent on 11 October 2021
40Hz ASSR: sounds that change our thoughts about schizophrenia Sent on 31 August 2021
Clerkenwell Health and Transpharmation combine lab and human trials for psilocybin Sent on 09 August 2021
Translational endpoints for preclinical pain - improving your chances. Sent on 01 July 2021
Transpharmation aims for global standard. Let's talk about lab sustainability. Sent on 02 June 2021
Targeting the unmet medical need in Parkinson's Disease - the fastest growing neurological disorder. Sent on 15 April 2021
Gene therapies for body and brain in Duchenne Muscular Dystrophy, progress moves forward. Sent on 08 March 2020
Announcing Transpharmation Poland! Sent on 08 February 2020
Psilocybin: the power of mental reorganisation Sent on 06 December 2020

The future's bright for the magic mushroom.

Expansion to world class premises Sent on 04 November 2020

We are delighted to share our very exciting news with you!In January 2021, Transpharmation Ltd will be taking on additional laboratory and office space, operating from the first-class facilities at the renowned Discovery Park research centre in Kent.This location will become Transpharmation’s primary site.

Multiple therapeutic indications Sent on 05 October 2020

Transpharmation Ltd celebrate 10 years in business. See our latest neuroinflammation study being presented at the Annual Alzheimer's Drug Discovery Foundation conference.

Focus on pain Sent on 04 September 2020

September is pain awareness month and we are presenting our latest pain study 'The effect of a reduced streptozocin dose and social housing on well-being, mechanical hypersensitivity and burrowing behaviour in type-1 diabetic rodents' at the IASP virtual conference.